FDA Agrees to Oculis's Pivotal Optic Neuritis Trial Design, De-risking Path to Market
OCS sits 85% above its 52-week low of $16.
Summary
Oculis has announced a Special Protocol Assessment (SPA) agreement with the FDA for PIONEER-1, its first registrational trial evaluating Privosegtor for optic neuritis (ON). This formal agreement confirms that the trial's design and planned analysis are sufficient to support a future New Drug Application (NDA) submission, significantly de-risking the regulatory pathway for the drug. Privosegtor, which has already received FDA Breakthrough Therapy and EMA PRIME designations, targets a potential $7 billion U.S. market in acute optic neuropathies. This milestone provides critical clarity and validation for Oculis's lead neuro-ophthalmology candidate, following positive Phase 2 ACUITY trial results, and is a material positive development for the company.
At the time of this announcement, OCS was trading at $29.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.00 to $30.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.